Breaking News, Collaborations & Alliances

Santhera, Ikris Sign Agreement for Distribution of AGAMREE in India

Will increase global access to AGAMREE for patients with Duchenne muscular dystrophy.

Author Image

By: Charlie Sternberg

Associate Editor

Santhera Pharmaceuticals has signed an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. The agreement has a 5-year term, and Santhera will receive a percentage of net sales, in line with previous distribution agreements. Sales are expected to begin in Q4 2025 on a named patient basis. Dario Eklund, CEO of Santhera, said: “We are p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters